

Conference Dinner Sponsor

Official Trainee Dinner Sponsor

Official Poster Session and Lunch Time Sponsor

Official Poster Session and Lunch Time Sponsor





GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission. For more information, visit grail.com.
This will close in 0 seconds
Detection of solid tumours at the early stage is associated with a better possibility of cure and survival. In addition, minimally invasive cancer tests that provide patient-specific, comprehensive treatment options can bring meaningful outcomes for treating and monitoring advanced/ refractory/ rare cancers. Datar Cancer Genetics UK Private Limited (DCG) has unique value portfolio that offers all of the above. Our liquid biopsy tests span across multicancer screening, early detection, comprehensive therapy recommendation, and cancer monitoring. These tests are performed in DCG UK’s fully accredited and equipped laboratory space, needing clients only to send the blood samples in DCG-provided blood collection kits. We deliver the comprehensive results within 10-12 working days. Our tests are CE-marked, IVD regulated under directive 98/79/EC. Our laboratory facility is CAP and CLIA accredited, working under ISO15189 QMS and is located at the Surrey Research Park, Guildford, United Kingdom.
DCG UK offers innovative tests for screening and diagnosis of solid organ cancers cancer based on detecting the presence of Circulating Tumour Cells (CTCs). CTCs are malignant cells shed by tumors into the vasculature and are a potent analyte for non-invasive diagnosis of cancer. DCG has a novel approach for the negative enrichment of CTCs from peripheral blood samples with proprietary chemistry that selectively kills non-malignant cells to enrich the desired CTCs, enhancing the clinical sensitivity. We combine our propriety CTC based technology and the power of genomics to provide solutions to various stages of cancer diagnosis and management.
For more details on the technology and publications, please visit: https://uk.datarpgx.com/
This will close in 0 seconds
Elypta is a Swedish cancer detection company focused on reducing cancer mortality by enabling earlier detection and improved monitoring.
The metabolism-based liquid biopsy platform in development measures a novel panel of biomarkers and utilizes machine learning algorithms to generate cancer-type specific GAGome scores.
Elypta is advancing a broad study program across different cancers, including multi-cancer early detection applications, with the first indication expected to be early detection of recurrence in renal cell carcinoma.
To learn more, see www.elypta.com
This will close in 0 seconds
We are a biopharmaceutical company that is driven by science, united by science, and every day, we push the boundaries of science to deliver life-changing medicines.
In Oncology, we have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. Our broad pipeline of next-generation medicines, together with our focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.
This will close in 0 seconds
PacBio is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. PacBio products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB® short read sequencing technologies. PacBio products address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. In cancer research and oncology, PacBio HiFi long-read technology provides a more complete view of the cancer genome and transcriptome, enabling discovery of novel variants in all variant classes including structural variants, isoforms, and fusions, while our emerging SBB® short read sequencing technology enables highly sensitive detection of ctDNA with reduced sequencing depth in liquid biopsy applications.
This will close in 0 seconds
At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re solving healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.
Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS - wherever they live, whatever their circumstances.
In 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.26 billion to the UK economy, supporting over 21,000 jobs.
Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.
That’s what makes us who we are. That’s what makes us Roche UK. For more information, please visit www.roche.co.uk.
This will close in 0 seconds
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information, please visit olink.com. Olink® is a registered trademark of Olink Proteomics AB.
At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re solving healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support. Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS - wherever they live, whatever their circumstances. In 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.26 billion to the UK economy, supporting over 21,000 jobs. Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones. That’s what makes us who we are. That’s what makes us Roche UK. For more information, please visit www.roche.co.uk.
This will close in 0 seconds